The Role of the GH/IGF System in Pituitary Tumorigenesis

Abstract

Pituitary adenomas are mostly benign tumours that originate from differentiated anterior pituitary cells. Altered expression of growth factors or their receptors could enhance clonal expansion of pituitary adenoma cells. GHRH overstimulation or an activating point mutation in the Gsa-subunit leads to increased GH secretion and tumour formation. In contrast, IGF-I suppresses basal and GHRH-stimulated GH secretion in pituitary adenoma cells, whereas prolactin secretion is unaffected. Somatostatin analogues and pegvisomant, a novel growth hormone-receptor antagonist, results in a reduction of serum IGF-I levels and clinical improvement in patients suffering from pituitary adenoma. Thus, this review focuses on the role of the growth hormone/insulin-like growth factor system in pituitary tumorigenesis with particular focus on the genetic alterations described in pituitary adenomas up to now.

Pituitary - Adenoma - GHRH - Growth hormone - Insulin-like growth factor

References

• 1 Webster J, Scanlon M F. Growth factors and the anterior pituitary.  Baillieres Clin Endocrinol Metab. 1991;  5 699-726
• 2 Kineman R D, Teixeira L T, Amargo G V, Coschigano K T, Kopchick J J, Frohman L A. The effect of GHRH on somatotrope hyperplasia and tumor formation in the presence and absence of GH signaling.  Endocrinology. 2001;  142 3764-3773
• 3 Vallar L, Spada A, Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas.  Nature. 1987;  330 566-568
• 4 Lyons J, Landis C A, Harsh G, Vallar L, Grunewald K, Feichtinger H, Duh Q Y, Clark O H, Kawasaki E, Bourne H R, McCormick F. Two G protein oncogenes in human endocrine tumors.  Science. 1990;  249 655-659
• 5 Weinstein L S, Shenker A, Gejman P V, Merino M J, Friedman E, Spiegel A M. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome.  N Eng J Med. 1991;  325 1688-1695
• 6 Johnson M C, Codner E, Eggers M, Mosso L, Rodriguez J A, Cassorla F. Gsp mutations in Chilean patients harboring growth hormone-secreting pituitary tumors.  J Pediatr Endocrinol Metab. 1999;  12 381-387
• 7 Akintoye S O, Chebli C, Booher S, Feuillan P, Kushner H, LeRoith D, Cherman N, Bianco P, Wientroub S, Robey P G, Collins M T. Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome.  J Clin Endocrinol Metab. 2002;  87 5104-5112
• 8 Zhuang Z, Ezzart S Z, Vortmeyer A D, Huang S, Agarwal S K, Guru S C, Manickamp P, Debelenko L V, Kester M B, Olufemi S E, Heppner C, Crabtree J S, Burns A L, Spiegel A M, Marx S J, Chandrasekharappa S C, Liotta L A, Asa S L, Lubensky I A. Mutations of the MEN-1 tumor suppressor gene in pituitary tumors.  Cancer Res. 1997;  57 5446-5451
• 9 Hermans M M, Lips C J, Bravenboer B. Growth hormone overproduction in a patient with multiple endocrine neoplasia type I.  J Intern Med. 2000;  248 525-530
• 10 Burgess J R, Shepherd J J, Parameswaran V, Hoffman L, Greenaway T M. Somatotrophinomas in multiple endocrine neoplasia type 1: a review of clinical phenotype and insulin-like growth factor-1 levels in a large multiple endocrine neoplasia type 1 kindred.  Am J Med. 1996;  100 544-547
• 11 Tanaka C, Yoshimoto K, Yamada S. Absence of germ-line mutations of the multiple endocrine neoplasia type 1 (MEN1) gene in familial pituitary adenoma in contrast to MEN1 in Japanese.  J Clin Endocrinol Metab. 1998;  83 960-965
• 12 Pei L, Melmed S. Isolation and characterization of a pituitary tumor-specific transforming gene.  Mol Endocrinol. 1997;  11 433-441
• 13 Molitch M E. Pituitary incidentalomas.  Endocrinol Metab Clinics North Am. 1997;  26 725-740
• 14 Pagesy P, Li J Y, Kujas M, Peillon F, Delalande O, Visot A, Derome P. Apparently silent somatotroph adenomas.  Pathol Res Pract. 1991;  187 950-956
• 15 Hirsch W, Zumkeller W, Teichler H, Jassoy A, Schluter A, Langer T. Microadenomas of the pituitary gland in children with and without hypophyseal dysfunction in magnetic resonance imaging.  J Pediatr Endocrinol Metab. 2002;  15 157-162
• 16 Colao A, Amato G, Pedroncelli A M, Baldelli R, Grottoli S, Gasco V, Petretta M, Carella C, Pagani G, Tambura G, Lombardi G. Gender- and age-related differences in the endocrine parameters of acromegaly.  J Endocrinol Invest. 2002;  25 532-538
• 17 Ferretti E, Jaffrain Rea M L, Asteria C, Di Stefano D, Esposito V, Ferrante L, Daniele P, Tiberti C, Gallucci M, Bosman C, Alesse E, Gulino A, Beck-Peccoz P, Tamburrano G. Two familial giant pituitary adenomas associated with overweight: clinical, morphological and genetic features.  Eur J Endocrinol. 2001;  144 227-235
• 18 Kurtkaya-Yapicier O, Scheithauer B W, Carney J A, Kovacs K, Horvath E, Stratakis C A, Vidal S, Vella A, Young W F Jr, Atkinson J L, Lloyd R V, Kontogeorgos G. Pituitary adenoma in Carney complex: an immunohistochemical, ultrastructural, and immunoelectron microscopic study.  Ultrastruct Pathol. 2002;  26 345-353
• 19 De Marinis L, Zuppi P, Valle D, Mancini A, Bianchi A, Lauriola L, Pasquini P, Anile C, Maira G, Giustina A. A retrospective hormonal and immunohistochemical evaluation of 47 acromegalic patients: prognostic value of preoperative plasma prolactin.  Horm Metab Res. 2002;  34 137-143
• 20 Shimon I, Nass D, Gross D J. Pituitary macroadenoma secreting thyrotropin and growth hormone: remission of bihormonal hypersecretion in response to lanreotide therapy.  Pituitary. 2001;  4 265-269
• 21 Florio T, Thellung S, Corsaro A, Bocca L, Arena S, Pattarozzi A, Villa V, Massa A, Diana F, Schettini D, Barbieri F, Ravetti J L, Spaziante R, Giusti M, Schettini G. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.  Clin Endocrinol (Oxf). 2003;  59 115-128
• 22 Hofland L J, Velkeniers B, vd Lely A J, van Koetsveld P M, Kazemzadeh M, Waaijers M, Hooghe-Peters E L, Lamberts S W. Long-term in-vitro treatment of human growth hormone (GH)-secreting pituitary adenoma cells with octreotide causes accumulation of intracellular GH and GH mRNA levels.  Clin Endocrinol (Oxf). 1992;  37 240-248
• 23 Ezzat S, Kontogeorgos G, Redelmeier D A, Horvath E, Harris A G, Kovacs K. In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide.  Eur J Endocrinol. 1995;  133 686-690
• 24 Trainer P J, Drake W M, Katznelson L, Freda P U, Herman-Bonert V, van der Lely A J, Dimaraki E V, Stewart P M, Friend K E, Vance M L, Besser G M, Scarlett J A, Thorner M O, Parkinson C, Klibanski A, Powell J S, Barkan A L, Sheppard M C, Malsonado M, Rose D R, Clemmons D R, Johannsson G, Bengtsson B A, Stavrou S, Kleinberg D L, Cook D M, Phillips L S, Bidlingmaier M, Strasburger C J, Hackett S, Zib K, Bennett W F, Davis R J. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.  N Engl J Med. 2000;  342 1171-1177
• 25 Wang L, Yang H, Adamo M L. Glucose starvation reduces IGF-I mRNA in tumor cells: evidence for an effect on mRNA stability.  Biochem Biophys Res Commun. 2000;  269 336-346
• 26 Yokoyama S, Thapar K, Kovacs K, Stefaneanu L. Localization of insulin-like growth factor-II mRNA in human pituitary adenomas.  Virchows Arch. 1998;  432 241-246
• 27 Atkin S L, Landolt A M, Foy P, Jeffreys R V, Hipkin L, White M C. Effects of insulin-like growth factor-I on growth hormone and prolactin secretion and cell proliferation of human somatotrophinomas and prolactinomas in vitro.  Clin Endocrinol (Oxf). 1994;  41 503-509
• 28 Yamashita S, Weiss M, Melmed S. Insulin-like growth factor I regulates growth hormone secretion and messenger ribonucleic acid levels in human pituitary tumor cells.  J Clin Endocrinol Metab. 1986;  63 730-735
• 29 Otsuka F, Tamiya T, Yamauchi T, Ogura T, Ohmoto T, Makino H. Quantitative analysis of growth-related factors in human pituitary adenomas. Lowered insulin-like growth factor-I and its receptor mRNA in growth hormone-producing adenomas.  Regul Pept. 1999;  83 31-38
• 30 Renner U, Mojto J, Arzt E, Lange M, Stalla J, Muller O A, Stalla G K. Secretion of polypeptide growth factors by human nonfunctioning pituitary adenoma cells in culture.  Neuroendocrinology. 1993;  57 825-834
• 31 Shimokawa I, Higami Y, Tsuchiya T, Otani H, Komatsu T, Chiba T, Yamaza H. Life span extension by reduction of the growth hormone-insulin-like growth factor-1 axis: relation to caloric restriction.  FASEB J. 2003;  17 1108-1109